Nii O. Koney MD, MBA, Abstract Co-Author: Nothing to Disclose

Yi Chen Zhang MD, Presenter: Nothing to Disclose

Elina Zaretsky MD, MA, Abstract Co-Author: Nothing to Disclose

Munir Ghesani MD, Abstract Co-Author: Nothing to Disclose

E. Gordon Depuey MD, Abstract Co-Author: Consultant, BioClinica, Inc Consultant, ICON plc Steering Committee, Adenosine Therapeutics, LLC

Alexander Cates Kagen MD, Abstract Co-Author: Speakers Bureau, Bayer AG

There is controversy over the utility of PSA as a screening tool because of its inability to differentiate indolent from aggressive cancer types. Molecular imaging is well positioned to address this challenge. Although the current workhorse for molecular imaging, 18F-FDG, is not effective in prostate cancer, several new agents have been/are being developed. For example, 11C- or 18F-labeled choline are emerging tracers for detecting local and metastatic prostate cancer. We will review the latest advances in the use of molecular imaging to screen and diagnose prostate cancer. We will evaluate the perceived clinical relevance of current and emerging tracers using preliminary results from a survey of practicing referring clinicians at our institution that show awareness of molecular imaging and need to demonstrate superiority over conventional imaging as a guide  

Introduction and Background on Molecular Imaging in Prostate Cancer Review of current and emerging prostate cancer imaging tracers Review of imaging protocol: patient selection, patient preparation, radiopharmaceutical preparation Evaluation of clinical relevance utilizing preliminary results from a survey of practicing referring clinicians  

http://abstract.rsna.org/uploads/2014/14019730/14019730_ugo4.pdf

Koney, N, Zhang, Y, Zaretsky, E, Ghesani, M, Depuey, E, Kagen, A, Clinical Relevance of Emerging Molecular Imaging Modalities in Prostate Cancer.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14019730.html